Citadel Advisors’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-75,551
| Closed | -$2.6M | – | 11888 |
|
|
2020
Q3 | $2.6M | Sell |
75,551
-176,464
| -70% | -$3.76M | ﹤0.01% | 4239 |
|
|
2020
Q2 | $4.21M | Sell |
252,015
-9,486
| -4% | -$161K | ﹤0.01% | 3328 |
|
|
2020
Q1 | $3.77M | Buy |
261,501
+133,108
| +104% | +$3.4M | ﹤0.01% | 3112 |
|
|
2019
Q4 | $4.3M | Sell |
128,393
-107,178
| -45% | -$3M | ﹤0.01% | 3265 |
|
|
2019
Q3 | $4.93M | Buy |
235,571
+15,955
| +7% | +$326K | ﹤0.01% | 3133 |
|
|
2019
Q2 | $4.57M | Buy |
219,616
+101,081
| +85% | +$2.08M | ﹤0.01% | 3223 |
|
|
2019
Q1 | $2.65M | Sell |
118,535
-55,144
| -32% | -$1.3M | ﹤0.01% | 3992 |
|
|
2018
Q4 | $4.15M | Buy |
173,679
+133,564
| +333% | +$3.46M | ﹤0.01% | 3045 |
|
|
2018
Q3 | $1.09M | Buy |
40,115
+624
| +2% | +$17.6K | ﹤0.01% | 5390 |
|
|
2018
Q2 | $1.06M | Buy |
39,491
+29,627
| +300% | +$907K | ﹤0.01% | 5115 |
|
|
2018
Q1 | $314K | Sell |
9,864
-13,269
| -57% | -$467K | ﹤0.01% | 6671 |
|
|
2017
Q4 | $875K | Sell |
23,133
-536,508
| -96% | -$17.3M | ﹤0.01% | 4844 |
|
|
2017
Q3 | $13.9M | Buy |
559,641
+542,111
| +3,092% | +$11.7M | 0.01% | 1338 |
|
|
2017
Q2 | $360K | Buy |
+17,530
| New | +$334K | ﹤0.01% | 5604 |
|
|
2017
Q1 | – | Sell |
-34,868
| Closed | -$713K | – | 8279 |
|
|
2016
Q4 | $713K | Buy |
34,868
+17,924
| +106% | +$366K | ﹤0.01% | 4351 |
|
|
2016
Q3 | $254K | Sell |
16,944
-279
| -2% | -$3.77K | ﹤0.01% | 5950 |
|
|
2016
Q2 | $186K | Buy |
+17,223
| New | +$234K | ﹤0.01% | 5892 |
|
Citadel Advisors's AIMT Position: Q4 2020 in Review
Citadel Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 75,551 shares — an estimated $2.6M sold.
Citadel Advisors first reported a position in AIMT in Q2 2016 and held it in 17 quarters. The position peaked at $13.9M in Q3 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Citadel Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 75,551 Aimmune Therapeutics shares in Q4 2020, an estimated $2.6M.
- Citadel Advisors first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 17 quarters.
- Citadel Advisors's Aimmune Therapeutics position peaked at $13.9M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.